← SynDRA
SUVOREXANT
SynDRA canonical compound SYN0022220 — structure-anchored drug synonym record
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | HCRTR2 |
|---|
| Mechanism of action | Orexin receptor antagonist |
|---|
All known targets
- HCRTR2
- HCRTR1
- Hcrtr1
- Hcrtr2
Mechanisms of action (all sources)
- Orexin receptor antagonist
- HCRTR2 ANTAGONIST
- HCRTR1 ANTAGONIST
- HCRTR2 MODULATOR
Drug classes
- Central Nervous System Agents
- Central Nervous System Depressants
- Hypnotics and Sedatives
- Neurotransmitter Agents
- Orexin Receptor Antagonists
- Sleep Aids, Pharmaceutical
- P-Glycoprotein Inhibitors
- Cytochrome P450 3A Inhibitors
- Orexin Receptor Antagonist
ATC classes
- N05C · HYPNOTICS AND SEDATIVES
Cross-references
Synonyms
- MK-4305
- belsomra
- MK4305
- Belsomra
- Suvorexant component of belsomra
- MK 4305
- BELSOMRA
- UNII-081L192FO9
- Suvorexant (MK-4305)
- [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone
- (R)-(4-(5-Chlorobenzo[d]oxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
- CHEMBL1083659
- CHEBI:82698
- 081L192FO9
- C23H23ClN6O2
- ((7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
- BELSOMRA COMPONENT SUVOREXANT
- suvorexantum
- RefChem:56329
- DTXCID0068107
- N05CM19
- MFCD22377755
- Suvorexant [USAN:INN]
- Belsomra (TN)
- SUV
- SUVOREXANT [MI]
- SUVOREXANT [INN]
- SUVOREXANT [JAN]
- Suvorexant (JAN/USAN)
- SUVOREXANT [USAN]
- Suvorexant; MK 4305
- SUVOREXANT [VANDF]
- SUVOREXANT [WHO-DD]
- orb146219
- GTPL2890
- SCHEMBL1586289
- SCHEMBL13372948
- SCHEMBL29357712
Reported adverse events
- Abnormal dreams
- Cataplexy
- Cough
- Depression
- Dizziness
- Dry mouth
- Gastrointestinal disorder
- Hallucination
- Headache
- Somnolence
- Upper respiratory tract infection
Look up SUVOREXANT in the interactive SynDRA portal →